Cargando…

mTOR signaling mediates ILC3-driven immunopathology

Innate lymphoid cells (ILCs) have a protective immune function at mucosal tissues but can also contribute to immunopathology. Previous work has shown that the serine/threonine kinase mammalian target of rapamycin complex 1 (mTORC1) is involved in generating protective ILC3 cytokine responses during...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teufel, Claudia, Horvath, Edit, Peter, Annick, Ercan, Caner, Piscuoglio, Salvatore, Hall, Michael N., Finke, Daniela, Lehmann, Frank M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528695/ https://www.ncbi.nlm.nih.gov/pubmed/34341503 http://dx.doi.org/10.1038/s41385-021-00432-4

Ejemplares similares

Microbiota-induced tissue signals regulate ILC3-mediated antigen presentation
por: Lehmann, Frank Michael, et al.
Publicado: (2020)

Adenylosuccinate lyase is oncogenic in colorectal cancer by causing mitochondrial dysfunction and independent activation of NRF2 and mTOR-MYC-axis
por: Taha-Mehlitz, Stephanie, et al.
Publicado: (2021)

Molecular damage in cancer: an argument for mTOR-driven aging
por: Blagosklonny, Mikhail V.
Publicado: (2011)

Where is mTOR and what is it doing there?
por: Betz, Charles, et al.
Publicado: (2013)

Transcription factor-driven regulation of ILC1 and ILC3
por: Schroeder, Jan-Hendrik, et al.
Publicado: (2022)

Maintenance of Immune Homeostasis through ILC/T Cell Interactions
por: von Burg, Nicole, et al.
Publicado: (2015)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

IL‐38 prevents induction of trained immunity by inhibition of mTOR signaling
por: de Graaf, Dennis M., et al.
Publicado: (2021)

Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver
por: Spormann, Luise, et al.
Publicado: (2020)

Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2020)

Combined HASPIN and mTOR inhibition is synergistic against KRAS-driven carcinomas
por: Xu, Chenyue, et al.
Publicado: (2022)

HIV-1 replication and latency are balanced by mTOR-driven cell metabolism
por: Crater, Jacqueline M., et al.
Publicado: (2022)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

Regulation of human mTOR complexes by DEPTOR
por: Wälchli, Matthias, et al.
Publicado: (2021)

mTOR and lysosome regulation
por: Puertollano, Rosa
Publicado: (2014)

mTOR, autophagy, and reprogramming
por: Tang, Bor Luen
Publicado: (2014)

Targeting glutaminase and mTOR
por: Tanaka, Kazuhiro, et al.
Publicado: (2015)

mTOR in cerebrovascular disease
por: Van Skike, Candice E., et al.
Publicado: (2019)

mTOR and Tumor Cachexia
por: Duval, Adrian P., et al.
Publicado: (2018)

Double agent mTOR
por: Danzer, Steve C.
Publicado: (2019)

mTOR in Human Diseases
por: Dormond, Olivier
Publicado: (2019)

Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
por: Renna, Maurizio
Publicado: (2016)

Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia
por: Lee, Keunwook, et al.
Publicado: (2012)

Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype
por: Ho, Alan L., et al.
Publicado: (2012)

The mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trials
por: Malley, Cian O., et al.
Publicado: (2015)

mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer
por: Mashima, Tetsuo, et al.
Publicado: (2017)

Selectivity of mTOR-Phosphatidic Acid Interactions Is Driven by Acyl Chain Structure and Cholesterol
por: Żelasko, Jolanta, et al.
Publicado: (2021)

mTOR inhibition suppresses Myc-driven polyposis by inducing immunogenic cell death
por: Leibowitz, Brian J., et al.
Publicado: (2023)

mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging
por: Węsierska-Gądek, Józefa
Publicado: (2010)

Plasticity and mTOR: Towards Restoration of Impaired Synaptic Plasticity in mTOR-Related Neurogenetic Disorders
por: Gipson, Tanjala T., et al.
Publicado: (2012)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

AAA + ATPase Thorase inhibits mTOR signaling through the disassembly of the mTOR complex 1
por: Umanah, George K. E., et al.
Publicado: (2022)

mTOR sends T cells on their way
por: LeBrasseur, Nicole
Publicado: (2008)

The Paradox of Akt-mTOR Interactions
por: Vadlakonda, Lakshmipathi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_aap9dojulv987gh2fq5oee7lrk